Imago BioSciences

Merck Co
Biotech

Merck inks $1.4B blood cancer buyout to challenge BMS, Novartis

Merck is paying $1.35 billion to buy Imago for an oral LSD1 inhibitor that is in midphase trials in life-threatening diseases of the bone marrow.
Nick Paul Taylor Nov 21, 2022 8:00am
Red blood cells

Imago eyes $105M IPO to fuel blood cancer programs

Jul 12, 2021 11:47am
A headshot of Hugh Rienhoff

Imago BioSciences raises $80M to advance blood cancer therapy

Nov 19, 2020 8:00am